EGFR and non-small cell lung carcinoma: WES-based HLA assessment revealed relatively higher pre-treatment HLA-LOH in nMPR patients, and IHC of HLA-A also verified that the mechanism of immune escape existed in EGFR-mutant NSCLC when treated with immunotherapy (Figure 6D).